POTENTIAL METABOLITES OF TRICYCLIC NEUROLEPTICS: 2,8-DIHYDROXY AND 3,8-DIHYDROXY DERIVATIVES OF 10-(4-METHYLPIPERAZINO)--10,11-DIHYDRODIBENZO[b, f]THIEPIN*


Miroslav Protiva, Karel Šindelář, Zdeněk Šedivý and Josef РомукА́čек Research Institute for Pharmacy and Biochemistry, 130 00 Prague 3

Received February 6th, 1979

A synthesis of the title compounds II and III, potential metabolites of the neuroleptic agent perathiepin I, was carried out. A reaction of (2-iodo-5-methoxypheny)lacetic acid with 4-methoxythiophenol afforded the acid VI. The isomeric acid XI was obtained from 2-iodo-4-methoxybenzoic acid by reaction with 4-methoxythiophenol and via intermediates VIII-X. Both acids (VI, XI) were cyclized with polyphosphoric acid to dimethoxydibenzo[b,f]thiepin-10(11H)-ones XIIab which were transformed via the alcohols XIIIab to the chloro compounds XIVab. Substitution reactions with 1-methylpiperazine gave the piperazine derivatives IV and V and dimethoxydibenzo[b,f]thiepins XVab. The dimethoxy compounds IV and V were demethylated with boron tribromide to the diaminodiphenols II and III. The central depressant and cataleptic activity of compounds II - V is lower than that of the unsubstituted substance I.

10-(4-Methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (perathiepin, I) (ref.^{1,2}) exhibited in animal tests a strong tranquilizing and clear neuroleptic activity^{3,4} and became a basic substance of a new group of multipotent psychotropic agents⁵. When it appeared to be a clinically interesting tranquilizer, neuroleptic and antidepressant⁶⁻¹⁰, a rather broad programme of investigating its biotransformation was started which led to the identification of several metabolites^{11,12}. As standards for comparison with the metabolic products, some phenolic compounds were also prepared, *i.e.* perathiepin derivatives hydroxylated in the benzene nuclei: 2-hydroxy¹³, 3-hydroxy¹⁴, 6-hydroxy¹⁵ and 8-hydroxy derivative¹⁶; unsuccessful were the attempts to prepare the 7-hydroxy derivative¹⁷. Out of the dihydroxy derivatives, only the 2,3-dihydroxy derivative¹⁸ has been described until now. The present paper deals with the synthesis of two further dihydroxy derivatives of perathiepin I which were considered rather probable metabolites: the 2,8-dihydroxy (II) and 3,8-dihydroxy derivative (III).


Part CXXXIII in the series Neurotropic and Psychotropic Agents; Part CXXXII: This Journal 44, 2689 (1979).




I, $R^1 = R^2 = H$ *III*, $R^1 = 3$ -OH, $R^2 = OH$ *IV*, $R^1 = 3$ -OCH₃, $R^2 = OCH_3$, $R^2 = OCH_3$

The synthesis of compounds II and III made use of similar methods like in the preparation of the previously described hydroxy derivatives¹³⁻¹⁸. The first task was the synthesis of the diphenyl sulfide *o*-acetic acids VI and XI which were transformed in the second stage to the 2,8-dimethoxy and 3,8-dimethoxy derivatives of perathiepin (IV and V). The syntheses were concluded by demethylation of these ethers to the free phenols II and III.

The known (2-iodo-5-methoxyphenyl)acetic acid¹⁹ was used as the starting material in the 2.8-disubstituted series. Its reaction with 4-methoxythiophenol²⁰ in a boiling potassium hydroxide solution and in the presence of copper resulted in 5-methoxy-2-(4-methoxyphenylthio)phenyl]acetic acid (VI). Treatment with polyphosphoric acid in boiling toluene effected the cyclization and 2,8-dimethoxydibenzo [b, f] this pin--10(11H)-one (XIIa) was obtained in a good yield. Reduction with sodium borohydride in boiling aqueous ethanol gave the dimethoxy alcohol XIIIa which was transformed by treatment with hydrogen chloride in benzene to the chloro derivative XIVa. The substitution reaction with 1-methylpiperazine was carried out in boiling chloroform. The base IV was the main product; in a lower extent, elimination took place leading to 2,8- dimethoxydibenzo [b, f] thispin (XVa). Demethylation of compound IV was carried out by treatment with boron tribromide in chloroform at room temperature. The primary product was hydrolyzed with boiling aqueous ethanol and the obtained crude hydrobromide of the product afforded by decomposition with a sodium carbonate solution the crude phenolic base II; its purification yielded only about 25% of the pure substance. The high melting point of this base and its IR spectrum confirmed its character of an inner salt.








VII, R = COOH IX, $R = CH_2CI$ VIII, $R = CH_2OH$ X, $R = CH_2CN$ XI, $R = CH_2COH$

Collection Czechoslov. Chem. Commun. [Vol. 44] [1979]

In the 3,8-disubstituted series, 2-iodo-4-methoxybenzoic acid²¹ was condensed with 4-methoxythiophenol²⁰ similarly like in the preceding case and gave 4-methoxy--2-(4-methoxyphenylthio)benzoic acid (VII). Reduction with sodium dihydridobis-(2-methoxyethoxy)aluminate in benzene afforded the alcohol VIII which was transformed by treatment with thionyl chloride in the presence of pyridine to the substituted benzyl chloride IX. A reaction with sodium cyanide in dimethylformamide led to the nitrile X and its alkaline hydrolysis resulted in the homologous acid XI. The remaining steps had a similar course like in the preceding case: cyclization to the ketone XIIb, reduction to the alcohol XIIIb, conversion to the chloro compound XIVb. The substitution reaction with 1-methylpiperazine afforded the base V as the main product and 2,7-dimethoxydibenzo [b, f] this pin (XVb) as the minor product of the simultaneously proceeding elimination reaction. Demethylation of compound Vwas carried out with boron tribromide in dichloromethane. The primary product was hydrolyzed in this case with aqueous sodium hydroxide. The high-melting phenolic base III was obtained in a low yield and its identity was corroborated by spectra. Neutralization with maleic acid gave a crystalline maleate.



In formulae XII-XV: a, R = 2-OCH₃ b, R = 3-OCH₃

Compounds III (maleate sesquihydrate, VÚFB-12.425) and IV (maleate, VÚFB-12.424) were submitted to an orientation pharmacological evaluation from the point of view of the expected central depressant activity in the rota-rod test in mice and the neuroleptic activity in the test of catalepsy in rats. The compounds were evaluated in the form of the mentioned salts but the doses given were calculated for bases (Dr J. Metyšová, pharmacological department of this institute). Compounds II (base, VÚFB-12.494) and V (dimethanesulfonate monohydrate, VÚFB-12.393) were evaluated in a number of tests using the methods of the general pharmacological screening (Dr M. Bartošová, affiliated unit of this institute at Rosice n/L). For comparison, the medium lethal doses (LD $_{50}$, mice) and the medium effective doses of perathiepin I (ref.³) bringing about ataxia in mice and catalepsy in rats (ED $_{50}$) are given: LD $_{50}$ 42.3 mg/kg *i.v.*, 43 mg/kg orally; taxia, ED $_{50}$ 0-187 mg/kg *i.v.*, 24 mg/kg orally; catalepsy, ED $_{50}$ 10 mg/kg *i.p.*, 45 mg/kg orally.

Collection Czechoslov. Chem. Commun. [Vol. 44] [1979]

Compound H is little toxic; its LD_{50} is higher than 1 500 mg/kg orally. On the rota-rod, a dose of 300 mg/kg orally was still practically without effect; it is inactive in the test of catalepsy. In an oral dose of 100 mg/kg, it decreases the spontaneous locomotor activity in mice to 50%.

Compound III showed some activity in the rota-rod test: $ED_{50} = 0.73 \text{ mg/kg} \text{ i.v.}$ In the test of catalepsy, the ED_{50} is higher than 100 mg/kg *i.p.* (this dose brings about catalepsy in 40% rats).

Compound IV is less toxic than perathiepin: $LD_{50} = 170 \text{ mg/kg}$ orally. In both of the basic tests, it is less active. In the rota-rod test, the $ED_{50} = 10 \text{ mg/kg}$ orally. In the test of catalepsy, the ED_{50} is higher than 50 mg/kg orally (this dose brings about catalepsy in 40% animals).

Compound V is similarly toxic like perathiepin I, $LD_{50} = 50 \text{ mg/kg } i.v.$ In the rota-rod test, the $ED_{50} = 1 \text{ mg/kg } i.v.$, and in the test of catalepsy, the ED_{50} is approximately 10 mg/kg i.p. The compound inhibits very efficiently the spontaneous locomotor activity in mice; $ED_{50} =$ 0.1 mg/kg s.c.. In a dose of 0.1-0.5 mg/kg i.v., it prolongs the thiopental sleeping time to 200% of the control value (100%). On the other hand, a dose of 10 mg/kg i.v., does not influence the body temperature of rats and has not anticonvulsant activity (pentetrazol). The same dose exhibits in more than 50% mice analgesia in the Haffner test. A dose of 0.1-1.0 mg/kgi.v. reduces the hypertensive epinephrine reaction in rats by 50%. The compound also exhibits spasmolytic activity: a concentration of 1-10 µg/ml decreases the acetylcholine contractions of the isolated rat duodenum by 50%; a concentration of 0.1-1-0 µg/ml inhibits similarly the barium chloride contractions. On the isolated atrium of the rabbit heart, the substance has a negative inotropic effect (in a concentration of 50 µg/ml, it decreases inotropy by 25%). Finally, a hyperglycaemic effect in rats was found (doses of $25-50 \text{ mg/kg orally bring about an increase$ of the lood sugar level by <math>20%).

In conclusion it may be stated that the dihydroxy derivatives II and III have some central depressant activity but neuroleptically are inactive. It is in agreement with our previous experience with dihydroxy compounds of this series of neuroleptics^{18,22}. The dimethoxy compounds IV and V are a little more active but do not attain the activity of perathiepin I. A rather rich spectrum of activities was shown by the compound V, exhibiting also a significant adrenolytic and hypotensive effect which is typical for our series of neuroleptics.

Compounds II, IV and V in the form of the mentioned salts were also tested for antimicrobial activity in vitro towards a standard set of microorganisms (Dr J. Turinová and Dr A. Čapek, bacteriological department of this institute); microorganisms, numbers of compounds and the minimum inhibitory concentrations in $\mu g/ml$ (unless they exceed 100 $\mu g/ml$) are given: Staphylococcus progenes aureus, V 100; Escherichia coli, IV 50; Mycobacterium tuberculosis H37Rv, IV 6·25, V 12·5; Saccharomyces pasterianus, V 50; Trichophyton mentagrophytes, V 50. The diol II is thus inactive, whereas the ethers IV and V have a rather high tuberculostatic activity.

EXPERIMENTAL

The melting points of analytical preparations were determined in Kofler's block and are not corrected; the samples were dried *in vacuo* at 67 Pa over P_2O_5 at room temperature or at 77°C. The UV spectra (in methanol) were recorded with a Unicam SP 8000 spectrophotometer, the IR spectra (in Nujol unless stated otherwise) with a Unicam SP 200G spectrophotometer, ¹H-NMR spectra

Neurotropic and Psychotropic Agents

(in CDCl₃ unless stated otherwise) with a Tesla BS 487C (80 MHz) spectrometer and the mass spectra with a MS 902 (AEI) spectrometer. The homogeneity of the compounds was checked by thin layer chromatography on silica gel (Silufol).

4-Methoxy-2-(4-methoxyphenylthio)benzoic Acid (VII)

4-Methoxythiophenol²⁰ (61 g), 121·5 g 2-iodo-4-methoxybenzoic acid²¹ and 2 g "molecular" copper were successively added to a stirred solution of 106 g KOH in 1 l H₂O at 60°C and the mixture was refluxed for 10 h. It was then diluted with 31 hot H₂O, the solution filtered with charcoal and the warm filtrate acidified with hydrochloric acid. After standing overnight, the product was filtered, washed with H₂O and dried *in vacuo*; 110 g (87%), m.p. 183–187°C. Analytical sample, m.p. 194–197°C (aqueous ethanol). UV spectrum: λ_{max} 235 nm (log *e* 4·53), infl. 263 nm (4·17), infl. 301 nm (3·64). IR spectrum: 775, 825, 850, 880 (2 adjacent and solitary Ar–H), 932, 1235, 2550, (COOH), 1025, 1145, 1290 (ArOR), 1495, 1550, 1590 (Ar), 1675 cm⁻¹ (Ar. .COOH). For C₁₅H₁₄O₄S (290·3) calculated: 62·05% C, 4·86% H, 11·04% S; found: 62·13% C, 5-12% H, 11·05% S.

4-Methoxy-2-(4-methoxyphenylthio)benzyl Alcohol (VIII)

A suspension of 110 g VII in 880 ml benzene was stirred and treated at $35-40^{\circ}$ C over 45 min with 235 ml 65% solution of sodium dihydridobis(2-methoxyethoxy)aluminate in benzene, added dropwise. The resulting solution was stirred for 4 h, allowed to stand overnight, decomposed under stirring with a 10% NaOH solution and the benzene layer was separated. It was washed with H₂O dried (MgSO₄) and evaporated; 83 g (79%) crude product which was used for further work. A sample for analysis was distilled, b.p. 185–190°C/0·13 kPa. IR spectrum (film): 829, 874, 882 (2 adjacent and solitary Ar—H), 1031, 1249, 1290 (ArOR), 1051 (CH₂OH), 1494, 1573, 1600, 3075, 3140 (Ar), 3480 cm⁻¹ (OH). For C₁₅H₁₆O₃S (276·3) calculated: 65·19% C, 5·84% H, 11·60% S; found: 64·96% C, 6·21% H, 11·66% S.

4-Methoxy-2-(4-methoxyphenylthio)benzyl Chloride (IX)

A mixture of 74 g crude VIII and 25 g pyridine was stirred and treated at 10°C over 25 min with a solution of 37 g SOCl₂ in 500 ml benzene. The mixture was allowed to stand overnight, then stirred for 45 min at 40°C, cooled to 10°C and decomposed by addition of 160 ml H₂O. The benzene layer was washed with dilute hydrochloric acid and H₂O, dried with MgSO₄ and evaporated; 71 g (90%), m.p. 55–60°C. Analytical sample, m.p. 66–67°C (benzene-light petroleum). ¹H-NMR spectrum: δ 7·35 (d, $J = 8 \cdot 5$ Hz, 2 H, 2,6·H₂ in the methoxyphenylthio group), 7·26 (d, $J = 8 \cdot 5$ Hz, 1 H, 6-H), 6·85 (d, $J = 8 \cdot 5$ Hz, 2 H, 3,5·H₂ in the methoxyphenylthio group), 6·64 (mcd, $J = 8 \cdot 5$; 3·0 Hz, 1 H, 5-H), 6·50 (mcs, $J = 3 \cdot 0$ Hz, 1 H, 3-H), 4·71 (s, 2 H, ArCH₂Cl), 3·78 and 3·61 (2 s, 6 H, 2 OCH₃). For C_{1.5}H_{1.5}ClO₂S (294·8) calculated: 61·11% C, 5·13% H, 12·03% Cl, 10·88% S; found: 61·38% C, 5·34% H, 12·03% Cl, 10·79% S.

[4-Methoxy-2-(4-methoxyphenylthio)phenyl]acetonitrile (X)

A solution of 71 g IX in 160 ml dimethylformamide was treated with 35.5 g NaCN, the mixture stirred and heated for 8 h to $105-110^{\circ}$ C and evaporated *in vacuo*, the residue treated with 600 ml H₂O and the mixture extracted with benzene. The extract was washed with H₂O, dried with MgSO₄, filtered with charcoal and evaporated. The residue was crystallized from a mixture of benzene and light petroleum; 44 g (64%), m.p. 82-84°C. Analytical sample, m.p. 89-90°C

2992

(benzene-light petroleum). IR spectrum: 810, 830, 860 (2 adjacent and solitary Ar-H), 1030, 1048, 1230, 1252, 1290 (ArOCH₃), 1482, 1496, 1573, 1590, 1600 (Ar), 2264 cm⁻¹ (R—CN). For $C_{16}H_{13}NO_2S$ (285·4) calculated: 67·34% C, 5·30% H, 4·91% N, 11·23% S; found: 67·73% C, 5·54% H, 4·95% N, 11·60% S.

[5-Methoxy-2-(4-methoxyphenylthio)phenyl]acetic Acid (VI)

4-Methoxythiophenol²⁰ (42 g), 87 g (2-iodo-5-methoxyphenyl)acetic acid¹⁹ and 1 g Cu were successively added to a stirred solution of 69 g KOH in 700 ml H₂O at 55°C. The mixture was stirred and refluxed for 14 h. After cooling, it was filtered with charcoal and the filtrate acidified with dilute hydrochloric acid. The oily product was extracted with benzene, the extract was dried with MgSO₄ and evaporated; 61 g (68%), m.p. 69–73°C. Analytical sample, m.p. 79–81°C (aqueous ethanol). IR spectrum: 809, 826, 836, 857 (2 adjacent and solitary Ar—H), 960, 1240, 1709, 2555, 2625, 2740 (COOH), 1029, 1310 (ArOCH₃), 1500, 1576, 1596, 3010, 3090, 3100 cm⁻¹ (Ar). For C₁₆H₁₆O₄S (304·4) calculated: 63·14% C, 5·30% H, 10·53% S; found: 63·52% C, 5·52% H, 10·61% S.

[4-Methoxy-2-(4-methoxyphenylthio)phenyl]acetic Acid (XI)

A warm solution of 43 g X in 230 ml ethanol was added to a warm solution of 42 g KOH in 200 ml H_2O and the mixture was refluxed for 12 h. Ethanol was evaporated, the precipitated potassium salt was dissolved in 650 ml warm H_2O , the solution was washed with benzene, filtered with charcoal and the filtrate acidified with 1 : 1 dilute hydrochloric acid. After standing overnight at 0°C, the product was filtered, washed with H_2O and dried *in vacuo*; 44·7 g (98%), m.p. 114 to 116°C. Analytical sample, m.p. 119–121°C (aqueous ethanol). IR spectrum: 788, 818, 830, 861 (2 adjacent and solitary Ar—H), 950, 1173, 1239, 1280, 1300, 1689, 2640 (COOH), 1030, 1051 (ArOCH₃), 1490, 1563, 1601 cm⁻¹ (Ar). For C₁₆ H₁₆O₄S (304·4) calculated: 63·14% C, 5·30% H, 10·53% S.

2,8-Dimethoxydibenzo[b,f]thiepin-10(11H)-one (XIIa)

A mixture of 30 g VI, 300 g polyphosphoric acid and 130 ml toluene was stirred and refluxed for 1.5 h (bath temperature of 125°C). After cooling, it was decomposed with 700 g ice and water and the product extracted with benzene. The extract was washed with H₂O, 5% NaOH and H₂O, dried with MgSO₄, filtered with charcoal and the filtrate was evaporated *in vacuo*; 23 g (82%) residue, m.p. 122–127°C. Analytical sample, m.p. 142–143°C (benzene). UV spectrum: λ_{max} 235 nm (log ε 4:43), infl. 260 nm (4:15), 352 nm (3:64). IR spectrum: 816, 887, 898 (2 adjacent and solitary Ar—H), 1020, 1030, 1290 (ArOCH₃), 1560, 1572, 1598, 3050 (Ar), 1670 cm⁻¹ (ArCO). ¹H-NMR spectrum: δ 6:50–7:70 (m, 6 H, Ar—H), 4:30 (s, 2 H, ArCH₂CO), 3:75 (s, 6 H, 2 OCH₃). For C_{1.6}H₁₄O₃S (286·3) calculated: 67:11% C, 4:93% H, 11:20% S; found: 66:61% C, 5:01% H, 11:39% S.

3,8-Dimethoxydibenzo[b,f]thiepin-10(11H)-one (XIIb)

X1 (40 g) was cyclized with 400 g polyphosphoric acid in 150 ml toluene like in the preceding case; 30·2 g (81%) crude ketone, m.p. 102–103°C. Analytical sample, m.p. 106–108°C (benzene--light petroleum). UV spectrum: λ_{max} 236 nm (log e 4-45), infl. 259 nm (4·11), 292·5 nm (3·59), 347 nm (3·64). IR spectrum (KBr): 800, 811, 821, 855, 874, 899 (2 adjacent and solitary Ar—H), 1030, 1035, 1226, 1240, 1269, 1287, 1292 (ArOCH₃), 1490, 1560, 1600, 3000, 3067 (Ar), 1675

cm⁻¹ (ArCO). ¹H-NMR spectrum: δ 7·72 (mcs, J = 3.0 Hz, 1 H, 9-H), 7·47 (d, J = 8.0 Hz, 1 H, 6-H), 7·30 (d, J = 8.0 Hz, 1 H, 1-H), 7·17 (mcs, J = 2.5 Hz, 1 H, 4-H), 6·96 (mcd, J = 8.0 3.0 Hz, 1 H, 7-H), 6·85 (mcd, J = 8.0; 2·5 Hz, 1 H, 2-H), 4·28 (s, 2 H, ArCH₂CO), 3·78 (2 s, 6 H, 2 OCH₃). For C₁₆H₁₄O₃S (286·3) calculated: 67·11% C, 4·92% H, 11·20% S; found: 67·44% C, 5·10% H. 10·93% S.

2,8-Dimethoxy-10,11-dihydrodibenzo[b,f]thiepin-10-ol (XIIIa)

A suspension of 18.4 g XIIa in 300 ml ethanol was stirred and treated at 70°C dropwise with a solution of 0.85 g NaBH₄ in 9 ml H₂O containing 0.25 ml 20% NaOH. The mixture was refluxed for 5 h. After cooling, it was filtered and the filtrate evaporated *in vacuo*. The residue was treated with 200 ml H₂O and extracted with benzene. The extract was washed with 3% NaOH and H₂O, dried (MgSO₄), filtered with charcoal and evaporated under reduced pressure; 16.4 g (89%), m.p. 90–93°C. Analytical sample, m.p. 97–98°C (benzene-light petroleum). IR spectrum: 818, 885 (2 adjacent and solitary Ar–H), 1035, 1061 (CHOH in a cycle), 1239, 1281 (ArOCH₃), 1480, 1527, 1573, 1602 (Ar), 3400 cm⁻¹ (OH). For C₁₆H₁₆O₃S (288-4) calculated: 66.64% C, 5.59% H, 11-12% S; found: 66.71% C, 5-66% H, 11-10% S.

3,8-Dimethoxy-10,11-dihydrodibenzo[b,f]thiepin-10-ol (XIIIb)

XIIb (31 g) was reduced with 1-46 g NaBH₄ in 500 ml ethanol and 15 ml H₂O similarly like in the preceding case. There were obtained 31 g (100%) of the oily product which was crystallized from a mixture of benzene and light petroleum; 19 g (61%), mp. 777–79°C. Analytical sample, m.p. $81-83^{\circ}$ C (cyclohexane). IR spectrum (KBr): 806, 850, 872, 891, 900 (2 adjacent and solitary Ar–H), 1030, 1050 (CHOH in a cycle), 1253, 1270 (ArOCH₃), 1498, 1567, 1602, 3020 (Ar), 2850 (OCH₃), 3405 cm⁻¹ (OH). For C₁₆H₁₆O₃S (288·4) calculated: 66·64% C, 5·59% H, 11·12% S; found: 66·88% C, 5·75% H, 10·92% S.

10-Chloro-2,8-dimethoxy-10,11-dihydrodibenzo[b,f]thiepin (XIVa)

A solution of 13·3 g XIIIa in 180 ml benzene was saturated in the presence of 10 g CaCl₂ for 2·5 h with anhydrous HCl at 20°C. The mixture was allowed to stand overnight, filtered with charcoal and the filtrate evaporated *in vacuo*; 14·0 g (98%), mp. 148–151°C (benzene). ¹H-NMR spectrum: δ 7·40 and 7·32 (2 d, $J = 8\cdot0$ Hz, 4,6-H2), 7·05 (mcs, $J = 3\cdot0$ Hz, 1 H, 9-H), 6·81 (mcs, $J = 3\cdot0$ Hz, 1 H, 9-H), 6·81 (mcs, $J = 3\cdot0$ Hz, 1 H, 1-H), 6·68 (mcd, $J = 8\cdot0$; 3·0 Hz, 2 H, 3,7-H2), 5·80 (dd, $J = 4\cdot0$; 8·0 Hz, 1 H, Ar–CH–Cl), c. 3·75 (m, 2 H, ArCH₂), 3·74 (s, 6 H, 2 OCH₃). For C₁₆H₁₅ClO₂S (306·8) calculated: 62·63% C, 4·93% H, 11·56% Cl, 10·45% S; found: 62·86% C, 4·97% H, 11·66% Cl, 10·28% S.

10-Chloro-3,8-dimethoxy-10,11-dihydrodibenzo[b,f]thiepin (XIVb)

XIIIb (20.0 g) was processed similarly like in the preceding case. There were obtained 20.0 g (94%) crude product, m.p. 106–110°C. Analytical sample, m.p. 116–118°C (benzene). ¹H-NMR spectrum: δ 7.34 (d, J = 8.5 Hz, 1 H, 6-H), 7.14 (d, J = 8.5 Hz, 1 H, 1-H), 7.08 and 7.04 (2 mcs, J = 2.5 Hz, 2 H, 4,9-H₂), 6.75 and 6.70 (2 mcd, J = 8.5; 2:5 Hz, 2 H, 2,7-H₂), 5.80 (dd, J = 8.0; 4.0 Hz, 1 H, Ar–CH–CI), 3.90 and 3.60 (2 dd, J = 14.0; 4.0 and 14.0; 8.0 Hz, 2 H, ArCH₂), 3.72 (s, 6 H, 2 OCH₃). For C₁₆H₁₅ClO₂S (306.8) calculated: 62.63% C, 4.93% H, 11.56% Cl, 10.48% S.

2,8-Dimethoxy-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (IV)

A solution of 13.2 g XIVa and 12.9 g 1-methylpiperazine in 35 ml chloroform was refluxed for 6 h. Chloroform was evaporated *in vacuo*, the residue treated with 70 ml 3% NaOH and extracted with benzene. The extract was washed with H₂O and shaken with an excess of 1.25M-H₂SO₄. The solid sulfate was filtered off, combined with the aqueous layer of the filtrate and the suspension was made alkaline with NH₄OH. The base was extracted with benzene, the extract was dried (MgSO₄), filtered with charcoal and evaporated *in vacuo*; 12.3 g (78%) oily base. Neutralization with maleic acid in ethanol gave the maleate, m.p. 166–168°C (ethanol-ether). For C₂₅H₃₀. N₂O₆S (486-6) calculated: 61.71% C, 6.21% H, 5.76% N, 6.59% S; found: 62.13% C, 6.36% H, 5.65% N, 6.53% S.

The pure maleate was decomposed with NH₄OH and the base, isolated by extraction with ether, was used for recording the ¹H-NMR spectrum: δ 7.40 and 7.30 (2 d, J = 8.0 Hz, 2 H, 4,6-H₂), 7.20 (mes, J = 3.0 Hz, 1 H, 9-H), 6.80 (mes, J = 3.0 Hz, 1 H, 1-H), 6.60 (med, J = 8.0; 3.0 Hz, 2 H, 3,7-H₂), 3.00-4.00 (m, 3 H, ArCH₂CHAr), 3.88 and 3.85 (2 s, 6 H, 2 OCH₃), 2.70 (def. t, 4 H, CH₂N⁴CH₂ of piperazine), 2.50 (def. t, 4 H, CH₂N⁴CH₂ of piperazine), 2.30 (s, 3 H, NCH₃).

The benzene layer after the extraction of the base with dilute H_2SO_4 was washed with H_2O_1 dried and evaporated; 1:8g crude 2,8-dimethoxydibenzo[*b*,*f*]thiepin (*XVa*), m.p. 117-119°C (benzene). UV spectrum: $\lambda_{max} 228$ nm (log *a* '45), 262 nm (4·47), 305 nm (3·83), 359 nm (2·76). IR spectrum (KBr): 785, 832, 864 (2 adjacent and solitary Ar—H), 1034, 1239 (ArOCH₃), 1472, 1561, 1591, 3018 cm⁻¹ (Ar). ¹H-NMR spectrum: δ 6·60-7·40 (m, 8 H, Ar—H and CH=CH), 3·69 (s, 6 H, 2 OCH₃). For C₁₆H₁₄O₂S (270·3) calculated: 71·08% C, 5·22% H, 11·86% S; found: 71·36% C, 5·43% H, 11·90% S.

3,8-Dimethoxy-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (V)

The reaction of 14.8 g XIVb with 14.5 g 1-methylpiperazine in 40 ml chloroform was carried out like in the preceding case. The oily base was obtained in a yield of 14.0 g (79%). It crystallized after mixing with light petroleum, mp. 114–116°C. Analytical sample, mp. 117–118°C (benzene-light petroleum). IR spectrum: 814, 822, 856, 882, 899 (2 adjacent and solitary Ar–H), 1021, 1033, 1230, 1252 (ArOCH₃), 1469, 1483, 1500, 1602, 3012 (Ar), 2805 cm⁻¹ (OCH₃, NCH₃). ¹H-NMR spectrum: δ 7·30 and 7·12 (2 d, J = 8.5 Hz, 2 H, 1,6-H₂), 7·20 and 7·04 (2 mcs, J = 3.0 Hz, 2 H, 4,9-H₂), 6·80 and 6·60 (2 mcd, J = 8.5; 30 Hz, 2 H, 3,7-H₂), 3·00 to 4·00 (m, 3 H, ArCH₂CHAr), 3·70 (s, 6 H, 2 OCH₃), 2·66 (m, 4 H, CH₂N¹CH₂ of piperazine), 2·40 (m, 4 H, CH₂N⁴CH₂ of piperazine), 2·25 (s, 3 H, NCH₃). For C₂₁H₂₆N₂O₂S (370·5) calculated: 68·07% C, 7·07% H, 7·56% N, 8·65% S; found: 68·14% C, 7·23% H, 7·39% N, 8·61% S.

Dimethanesulfonate monohydrate, m.p. $171-174^{\circ}C$ (95% ethanol). For $C_{23}H_{34}N_2O_8S_3 + H_2O$ (580·7) calculated: $47\cdot57\%$ C, $6\cdot25\%$ H, $4\cdot82\%$ N, $16\cdot56\%$ S; found: $47\cdot86\%$ C, $6\cdot16\%$ H, $4\cdot76\%$ N, $16\cdot74\%$ S.

The neutral product was obtained in a yield of 2·4 g and was identified as 2,7-dimethoxydibenzo[b,f]thiepin (XVb) crystallizing from a mixture of benzene and light petroleum, m.p. 99–101°C. UV spectrum: λ_{max} 227 nm (log ϵ 4·50), 269 nm (4·12), 303 nm (3·90), infl. 340 nm (3·34). IR spectrum (KBr): 784 (*cis*-CH=CH), 827, 848, 866, 898 (2 adjacent and solitary Ar—H), 1030, 1218, 1250 (ArOCH₃), 1498, 1591, 1600, 3028, 3078 (Ar), 2855 cm⁻¹ (OCH₃), For, C₁₆H₁₄O₂S (270·3) calculated: 71·08% C, 5·22% H, 11·86% S; found: 70·64% C, 5·27% H, 11·58% S.

2,8-Dihydroxy-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thicpin (II)

A solution of 3.7 g IV in 40 ml chloroform was stirred and treated at 15°C with a solution of 150 g BBr₃ in 60 ml chloroform over 20 min. The mixture was stirred for 4 h at 22°C. Chloroform was evaporated *in vacuo*, the residue dissolved in a mixture of 150 ml ethanol and 50 ml H₂O and the solution was refluxed for 5 h. Ethanol was then evaporated *in vacuo* and the residue was treated with 120 ml 10% Na₂CO₃ solution. The precipitate was filtered and dried *in vacuo*; 3.45 g (m.p. 190–210°C). It was purified by extraction with boiling water and by crystallization from acetone; 0.9 g (26%), m.p. 247–249°C. UV spectrum: λ_{max} 260 nm infl. (log *e* 4.01), infl. 295 nm (3.52). IR spectrum: 792, 812, 881, 907 (2 adjacent and solitary Ar–H), 1153 (ArOH), 1478, 1581, 1610 (Ar), 2520 (NH⁺), 3380 cm⁻¹ (OH in a H bond). For C₁₉H₂₂N₂O₂S (342·4) calculated: 66.64% C, 6.48% H, 8.18% N, 9.36% S; found: 66.02% C, 6.66% H, 8.13% N, 9.68% S.

3,8-Dihydroxy-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (III)

A solution of 4·2 g V in 20 ml dichloromethane was stirred and treated dropwise with a solution of 11·3 g BBr₃ in 10 ml dichloromethane. The mixture was stirred for 5 h at room temperature and allowed to stand overnight. Dichloromethane was evaporated, the residue was treated with 25 ml 20% NaOH and 20 ml H₂O and the mixture stirred for 30 min at 90°C. After cooling, it was neutralized with acetic acid, the solid was extracted with dilute hydrochloric acid and the acid solution neutralized with 5% NaHCO₃ solution. The precipitated product was crystallized from a mixture of benzene and ethanol; 0·60 g (14%) of a benzene solvate, m.p. 235–239°C. Mass spectrum, m/e: 342·1398 (M⁺ corresponding to C₁₉H₂₂N₂O₂S). IR spectrum (KBr): 826, 869 (2 adjacent and solitary Ar–H), 1235, 1292 (ArOH), 1471, 1578, 1601 (Ar), 2830 (NCH₃), 3400 cm⁻¹ (OH). ¹H-NMR spectrum (CD₃SOCD₃): δ 9·40 (bs, 2 H, 2,0H), 7·30 (s, 2 H, 1/3 C₆H₆), 7·14 (d, $J = 8\cdot0$ Hz, 1 H, 6-H), 7·08 (d, $J = 8\cdot0$ Hz, 1 H, 1-H), 6·97 and 6·80 (2 mcs, $J = 3\cdot0$ Hz, 2 H, 4,9-H₂), 6·59 and 6·50 (2 mcd, $J = 8\cdot0$; 3·00 Hz, 2 H, 2,7-H₂), 2.80 to 4·00 (m, 3 H, ArCH₂CHAr), 2·50 (bs, 4 H, CH₂N¹CH₂ of piperazine), 2·20 (bs, 4 H, CH₂N⁴CH₂ of piperazine), 2·10 (s, 3 H, NCH₃). For C₁₉H₂₂N₂O₂S + 1/3 C₆H₆ (368·5) calculated: 68·45% C, 6·56% H, 7·60% N, 8·70% S; found: 67·55% C, 6·51% H, 7·22% N, 8·64% S.

Maleate sesquihydrate, m.p. $176-179^{\circ}C$ (aqueous acetone-ether). Mass spectrum, m/e (%): 342·1421 (M⁺ corresponding to $C_{19}H_{22}N_2O_2S$, 10), 299 (5), 285 (10), 271 (6), 257 (8), 242 (45), 181 (25), 99 (80), 70 (100), 58 (100). For $C_{23}H_{26}N_2O_6S + 1.5 H_2O$ (485·6) calculated: 56·89% C, 602% H, 5·77% N, 6·60% S; found: 57·00% C, 5·83% H, 5·76% N, 6·32% S.

The authors are indebted to Drs J. Holubek, E. Svåtek and M. Ryska (department of physical chemistry of this institute) for recording and interpreting the spectra reported, and to Mrs J. Komancová, Mrs V. Šmídová and Mrs J. Kropáčová (department of analytical chemistry of this institute) for carrying out the analyses.

REFERENCES

- Jílek J. O., Seidlová V., Svátek E., Protiva M., Pomykáček J., Šedivý Z.: Monatsh. Chem. 96, 182 (1965).
- 2. Jílek J. O., Svátek E., Metyšová J., Pomykáček J., Protiva M.: This Journal 32, 3186 (1967).
- 3. Metyšová J.: Activ. Nerv. Super. 8, 388 (1966).
- 4. Benešová O., Bohdanecký Z.: Activ. Nerv. Super. 8, 390 (1966).
- Protiva M., Jílek J. O., Metyšová J., Seidlová V., Jirkovský I., Metyš J., Adlerová E., Ernest I., Pelz K., Pomykáček J.: Farm. Sci. Tec. (Pavia) 20, 721 (1965).

Protiva, Šindelář, Šedivý, Pomykáček

- 6. Vinař O., Taussigová D.: Activ. Nerv. Super. 8, 394 (1966).
- 7. Náhunek K., Švestka J.: Activ. Nerv. Super. 8, 392 (1966).
- 8. Vinař O., Ledererová E., Baštecký J.: Activ. Nerv. Super. 9, 429 (1967).
- 9. Náhunek K., Švestka J., Rodová A., Mišurec J.: Activ. Nerv. Super. 9, 430 (1967).
- 10. Náhunek K.: Activ. Nerv. Super. 12, 93 (1970).
- 11. Queisnerová M., Svátek E., Macek K., Metyšová J.: Activ. Nerv. Super. 10, 335 (1968).
- 12. Queisnerová M., Svátek E., Macek K., Metyšová J.: Česk. Farm. 17, 248 (1968).
- Šindelář K., Holubek J., Dlabač A., Bartošová M., Protiva M.: This Journal 42, 2231 (1977).
- 14. Protiva M., Šindelář K., Šedivý Z., Metyšová J.: This Journal 44, 2108 (1979).
- 15. Protiva M., Šedivý Z., Metyšová J.: This Journal 40, 2667 (1975).
- 16. Šindelář K., Kakáč B., Svátek E., Metyšová J., Protiva M.: This Journal 38, 1579 (1973).
- 17. Valenta V., Bártl V., Dlabač A., Metyšová J., Protiva M.: This Journal 41, 3607 (1976).
- Šindelář K., Kakáč B., Holubek J., Svátek E., Ryska M., Metyšová J., Protiva M.: This Journal 41, 1396 (1976).
- 19. Archer S. (Sterling Drug, Inc.): U.S. 2 548 852 (17. 04. 51); Chem. Abstr. 46, 1042 (1952).
- 20. Wagner A. W.: Chem. Ber. 99, 375 (1966).
- Šindelář K., Jílek J. O., Metyšová J., Pomykáček J., Protiva M.: This Journal 39, 3548 (1974).
- 22. Šindelář K., Kopicová Z., Metyšová J., Protiva M.: This Journal 40, 3530 (1975).

Translated by the author (M.P.).

2996